Esperion Therapeutics ESPR Share-Based Payment - Unrecognized Cost of Nonvested Awards
Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's share-based payment - unrecognized cost of nonvested awards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's share-based payment - unrecognized cost of nonvested awards?
- Esperion Therapeutics (ESPR) reported share-based payment - unrecognized cost of nonvested awards of $4.8M in Q4 2025.
- How has Esperion Therapeutics's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
- Esperion Therapeutics's share-based payment - unrecognized cost of nonvested awards decreased by 0.0% year-over-year, from $4.8M to $4.8M.
- What is the long-term trend for Esperion Therapeutics's share-based payment - unrecognized cost of nonvested awards?
- Over 5 years (2020 to 2025), Esperion Therapeutics's share-based payment - unrecognized cost of nonvested awards has grown at a -29.1% compound annual growth rate (CAGR), from $26.8M to $4.8M.
- What does share-based payment - unrecognized cost of nonvested awards mean?
- This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.